Scarica l'app Stockscreener
69.15
1.05%
0.72
Dopo l'orario di chiusura:
69.41
0.26
+0.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
BofA Securities Adjusts Price Target on CRISPR Therapeutics AG to $93 From $78, Maintains Buy Rating - MarketScreener
CRSP: B of A Securities Raises Price Target to $93, Maintains Buy Rating | CRSP Stock News - GuruFocus
Crispr Therapeutics price target raised to $93 from $78 at BofA - TipRanks
Leerink Partnrs Has Optimistic Outlook of CRSP Q3 Earnings - MarketBeat
(CRSP) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Tick level data insight on CRISPR Therapeutics AG volatilityLayoff News & Real-Time Volume Surge Alerts - newser.com
Moran Wealth Management LLC Makes New Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
Visual analytics tools that track CRISPR Therapeutics AG performanceDip Buying & Safe Entry Zone Tips - newser.com
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells 1,076 Shares of Stock - MarketBeat
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 4,242 Shares of Stock - MarketBeat
Visualizing CRISPR Therapeutics AG stock with heatmaps2025 Bull vs Bear & Smart Money Movement Alerts - newser.com
CRISPR Therapeutics (CRSP) Plans to Sell $600 Million in Shares - GuruFocus
CRISPR Therapeutics files for $600M stock offering - MSN
CRISPR Therapeutics files for $600M stock offering (CRSP:NASDAQ) - Seeking Alpha
Interchange Capital Partners LLC Has $38,000 Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics files to offer up to $600 million in new common shares By Investing.com - Investing.com Australia
22,967 Shares in CRISPR Therapeutics AG $CRSP Bought by Concurrent Investment Advisors LLC - MarketBeat
Crispr Therapeutics (CRSP) general counsel sells $71k in shares By Investing.com - Investing.com South Africa
Kulkarni, CRISPR therapeutics CEO, sells $282k in shares - Investing.com
Crispr Therapeutics files to offer up to $600 million in new common shares - Investing.com India
Crispr Therapeutics AG Files $600M Share Offering - TipRanks
CRISPR Therapeutics AG Announces $600 Million Share Offering - TradingView
Key resistance and support levels for CRISPR Therapeutics AG2025 Sector Review & Safe Entry Point Alerts - newser.com
Analyzing net buyer seller activity in CRISPR Therapeutics AGPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com
3 Monster Stocks to Hold for the Next 10 Years - AOL.com
SyNTase Gene Editor Corrects Antitrypsin Deficiency In Vivo - CRISPR Medicine News
Blair William & Co. IL Reduces Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics AG (CRSP) Receives a Buy from Citizens JMP - The Globe and Mail
Is CRISPR Therapeutics AG stock cheap compared to fundamentalsIPO Watch & Fast Moving Market Watchlists - newser.com
Will CRISPR Therapeutics AG continue its uptrendMarket Performance Recap & Real-Time Stock Price Movement Reports - newser.com
Crispr Therapeutics: This Cheap Stock to Buy Is Up 65% in 2025 - Morningstar Canada
Crispr: Investors Waiting Patiently For In-Vivo - Seeking Alpha
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 6.1%Here's Why - MarketBeat
Crispr Therapeutics price target raised to $75 from $65 at Wells Fargo - TipRanks
Crispr Therapeutics AG: Promising Advancements in Gene Editing and Strategic Market Entry Justify Buy Rating - TipRanks
Citizens reiterates Market Outperform rating on CRISPR Therapeutics stock - Investing.com
CRISPR Therapeutics (CRSP) Is Up 7.9% After Unveiling CTX460 Gene Editing Data for AAT Deficiency Therapy – Has The Bull Case Changed? - Sahm
CRISPR Therapeutics AG stock retracement – recovery analysisMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Measuring CRISPR Therapeutics AG’s beta against major indicesJuly 2025 Levels & Real-Time Stock Entry Alerts - newser.com
Can Owais Metal and Mineral Processing Limited Compete Against Disruptor Stocks in Its SectorStraddle and Strangle Trades & Free Stay Ahead With Picks - earlytimes.in
CRISPR Therapeutics' (CRSP) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
4,245 Shares in CRISPR Therapeutics AG $CRSP Bought by Valeo Financial Advisors LLC - MarketBeat
Crispr Therapeutics AG: Buy Rating Backed by Innovative SyNTase Platform and Promising Preclinical Data - TipRanks
CRISPR Therapeutics AG Hits New 52-Week High of $78.47 - Markets Mojo
CRISPR Therapeutics (CRSP): Valuation Perspective Following Breakthrough SyNTase Preclinical Data and Pipeline Progress - Sahm
CRSP: Needham Reiterates Buy Rating with $81 Target Price | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Advancements in Gene Editing Justify Buy Rating - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 12-Month HighShould You Buy? - MarketBeat
CRSP Showcases Promising Preclinical Data for AATD Treatment - GuruFocus
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform - The Manila Times
CRISPR Therapeutics Highlights Potential Best-in-Class AATD Treatment with CTX460 at ESGCT 2025 Annual Congress - Quiver Quantitative
>90% mRNA correction: CRISPR Therapeutics' CTX460 raises serum AAT >5-fold and shows durable in vivo editing - Stock Titan
Combining machine learning predictions for CRISPR Therapeutics AG2025 EndofYear Setup & Community Consensus Stock Picks - newser.com
McElhenny Sheffield Capital Management LLC Invests $6.62 Million in CRISPR Therapeutics AG $CRSP - MarketBeat
Multi factor analysis applied to CRISPR Therapeutics AG2025 Key Highlights & High Return Stock Watch Alerts - newser.com
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - ADVFN
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):